The Myotonias and Susceptibility to Malignant Hyperthermia
Anesth Analg 2009; 109: 1054-64.
Finally, we identified 5 individuals we would consider to be at risk for malignant hyperthermia
due to rare variants in RYR1 and CACNA1S.
Recognizing and managing a malignant hyperthermia
crisis: guidelines from the European Malignant Hyperthermia
(MH) maybe considered rare, but it is remarkably lethal if left untreated.
A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia
. J Clin Psychopharmacol.
RYANODEX remains approved for the treatment of malignant hyperthermia
in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia
in patients at high risk.
To the Editor: Malignant hyperthermia
(MH) is a rare but potentially fatal, inherited skeletal muscle disorder that is mostly induced by the ingestion of the depolarizing relaxant, i.e., succinylcholine or volatile anesthetics.[sup] Its incidence is reportedly 1/5000 to 1/100,000 in general anesthesia patients, and children seem to be more susceptible than adults.[sup] According to MH treatment guidelines of the Malignant Hyperthermia
Association of the United States (MHAUS) and European Malignant Hyperthermia
Group (EMHG), dantrolene should be administered as soon as possible in suspected case.[sup], Unfortunately, dantrolene is not readily available worldwide.
NMS is a diagnosis of exclusion, so it should be differentiated from other conditions, including infection of central nervous system (CNS), agitated delirium, malignant catatonia, serotonin syndrome, malignant hyperthermia
must be eliminated in case of a suspicion of NMS; patients display a pathological response to the administration of muscle relaxants or general anaesthesia with severe hyperthermia and muscle stiffness.
Mutations in RYR1 gene, which causes abnormalities in the opening probability of the [Ca.sup.2+] channel, are also often associated to malignant hyperthermia
(MH) susceptibility, an inherited pharmacogenetic subclinical myopathy, characterized by a life-threatening hypermetabolic response to commonly used halogenated/volatile anesthetics (i.e., halothane, isofluorane) [8, 9].